UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

The lancet respiratory medicine, 2015-04, Vol.3 (4), p.301-309

2015

Volltextzugriff (PDF)

COVID and Lung Cancer

Current oncology reports, 2021-11, Vol.23 (11), p.134-134, Article 134

2021

Volltextzugriff (PDF)

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

The lancet oncology, 2013-10, Vol.14 (11), p.1104-1111

2013

Volltextzugriff (PDF)

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

The lancet oncology, 2018-11, Vol.19 (11), p.1468-1479

2018

Volltextzugriff (PDF)

Immunotherapy of brain metastases: breaking a "dogma"

Journal of experimental & clinical cancer research, 2019-10, Vol.38 (1), p.419-10, Article 419

2019

Volltextzugriff (PDF)

The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors

Frontiers in oncology, 2024-01, Vol.13, p.1308460

2024

Volltextzugriff (PDF)

The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis

Clinical and experimental medicine, 2023-09, Vol.23 (5), p.1551-1561

2023

Volltextzugriff (PDF)

Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report

International journal of molecular sciences, 2024-07, Vol.25 (14), p.7508

2024

Volltextzugriff (PDF)

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

The lancet respiratory medicine, 2018-06, Vol.6 (6), p.451-460

2018

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?

International journal of molecular sciences, 2023-08, Vol.24 (16), p.12622

2023

Volltextzugriff (PDF)

The future of mesothelioma treatment: time to shift gear

The lancet respiratory medicine, 2019-07, Vol.7 (7), p.554-555

2019

Volltextzugriff (PDF)

Challenges in lung cancer therapy during the COVID-19 pandemic

The lancet respiratory medicine, 2020-06, Vol.8 (6), p.542-544

2020

Volltextzugriff (PDF)

Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

Clinical cancer research, 2021-09, Vol.27 (17), p.4737-4745

2021

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Clinical cancer research, 2020-08, Vol.26 (16), p.4201-4205

2020

Volltextzugriff (PDF)

Immune Checkpoint Blockade in Malignant Mesothelioma

Seminars in oncology, 2015-06, Vol.42 (3), p.418-422

2015

Volltextzugriff (PDF)

Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma

European journal of cancer (1990), 2014-01, Vol.50 (1), p.121-127

2014

Volltextzugriff (PDF)

Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial

European journal of cancer (1990), 2024-03, Vol.199, p.113531-113531, Article 113531

2024

Volltextzugriff (PDF)

Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy

Archives of Endocrinology and Metabolism, 2020-08, Vol.64 (4), p.483-486

2020

Volltextzugriff (PDF)

SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines

European journal of cancer (1990), 2022-08, Vol.171, p.143-149

2022

Volltextzugriff (PDF)

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

The lancet respiratory medicine, 2021-06, Vol.9 (6), p.613-621

2021

Volltextzugriff (PDF)

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study

The lancet respiratory medicine, 2021-09, Vol.9 (9), p.969-976

2021

Volltextzugriff (PDF)

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

Cancer Immunology, Immunotherapy, 2013-06, Vol.62 (6), p.1021-1028

2013

Volltextzugriff (PDF)

Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications

Seminars in oncology, 2010-10, Vol.37 (5), p.460-467

2010

Volltextzugriff (PDF)

Immunotherapy in malignant pleural mesothelioma: a long story ended in success

Journal of cancer metastasis and treatment, 2022, Vol.8, p.44

2022

Volltextzugriff (PDF)

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Cancer Immunology, Immunotherapy, 2009-08, Vol.58 (8), p.1297-1306

2009

Volltextzugriff (PDF)

1 – 25 von 185

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(175)
Mit Volltextzugriff
(165)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

COVID and Lung Cancer

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Immunotherapy of brain metastases: breaking a "dogma"

The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors

The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis

Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach?

The future of mesothelioma treatment: time to shift gear

Challenges in lung cancer therapy during the COVID-19 pandemic

Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases

Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era

Immune Checkpoint Blockade in Malignant Mesothelioma

Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma

Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial

Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy

SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines

Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study

Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

Clinical Studies With Anti–CTLA-4 Antibodies in Non-melanoma Indications

Immunotherapy in malignant pleural mesothelioma: a long story ended in success

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Suchergebnisse filtern